Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction

International Journal of Impotence Research

Volumn 24, Issue 1, 2012, Pages 38-43

  Muniz, J J ^a   Lacchini, R ^a   Belo, V A ^a   Nobre, Y T D A ^b   Tucci Jr , S ^b   Martins, A C P ^b   Tanus Santos, J E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

erectile dysfunction; matrix metalloproteinases; tissue inhibitors of metalloproteinases

Indexed keywords

ANTIHYPERTENSIVE AGENT; GELATINASE A; GELATINASE B; INSULIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; ORAL ANTIDIABETIC AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; ZYMOGRAPHY;

ADULT; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENZYME INHIBITORS; ERECTILE DYSFUNCTION; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84855896280     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2011.44     Document Type: Article

References (35)

1. McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357: 2472-2481.
2. Chew KK, Finn J, Stuckey B, Gibson N, Sanfilippo F, Bremner A et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med 2010; 7: 192-202.
3. Hale TM, Hannan JL, Carrier S, deBlois D, Adams MA. Targeting vascular structure for the treatment of sexual dysfunction. J Sex Med 2009; 6(Suppl 3): 210-220.
4. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405-1411. (Pubitemid 38496346)
5. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87: 838-845. (Pubitemid 34204326)
6. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120: 151-157. (Pubitemid 46175775)
7. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res 2007; 19: 296-302. (Pubitemid 46701457)
8. Aversa A, Bruzziches R, Francomano D, Natali M, Gareri P, Spera G. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol 2010; 17: 38-47.
9. Schwartz BG, Kloner RA. How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. Int J Impot Res 2009; 21: 327-335.
10. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med 2006; 23: 198-203.
11. Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GTet al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51: 2045-2050. (Pubitemid 351680526)
12. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005; 45: 432-437. (Pubitemid 40315814)
13. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331. (Pubitemid 351707391)
14. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194-201.
15. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan Jr R, Rossi MA et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599-608.
16. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
17. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Brit J Pharmacol 2007; 152: 189-205. (Pubitemid 47517601)
18. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242.
19. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007; 33: 129-134.
20. Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Goncalves FM, Gerlach RF et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 2009; 408: 60-64.
21. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metallopro-teinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875-880.
22. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351. (Pubitemid 29367263)
23. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830. (Pubitemid 27246947)
24. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007; 40: 119-123. (Pubitemid 46014168)
25. Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC et al. Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 2009; 47: 888-891.
26. Makowski GS, Ramsby ML. Identification and partial characterization of three calcium- and zinc-independent gelati-nases constitutively present in human circulation. Biochem Mol Biol Int 1998; 46: 1043-1053. (Pubitemid 29004615)
27. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006; 47: 117-122. (Pubitemid 44378234)
28. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009; 42: 984-990.
29. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009; 403: 173-177.
30. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-498. (Pubitemid 47064570)
31. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
32. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metallo-proteinases (TIMPs). J Card Fail 2007; 13: 530-540. (Pubitemid 47371209)
33. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, StetlerStevenson M, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158: 1207-1215. (Pubitemid 32281283)
34. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-231. (Pubitemid 44110588)
35. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011;109:130-137.